887353-29-9

Basic information

• Product Name: 10-(T-BOC-AMINO)-1-DECYLBROMIDE
• Synonyms: 10-(T-BOC-AMINO)-1-DECYLBROMIDE;(10-BroModecyl)carbaMic Acid 1,1-DiMethylethyl Ester;10-(Boc-amino)-1-decyl bromide
• CAS NO: 887353-29-9
• Molecular Formula: C15H30BrNO2
• Molecular Weight: 336.31
• Product Categories: Miscellaneous Reagents
• Mol File: 887353-29-9.mol
• Article Data: 4

Chemical Properties

• Melting Point: 35-37°C
• Boiling Point: 396.6°C at 760 mmHg
• Flash Point: 193.6°C
• Appearance: /
• Density: 1.114g/cm³
• Vapor Pressure: 1.69E-06mmHg at 25°C
• Refractive Index: 1.472
• Storage Temp.: -20°C Freezer
• Solubility: Chloroform (Slightly), Methanol (Slightly)
• CAS DataBase Reference: 10-(T-BOC-AMINO)-1-DECYLBROMIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 10-(T-BOC-AMINO)-1-DECYLBROMIDE(887353-29-9)
• EPA Substance Registry System: 10-(T-BOC-AMINO)-1-DECYLBROMIDE(887353-29-9)

Safety Data

• Hazardous Substances Data: 887353-29-9(Hazardous Substances Data)

Usage

Chemical Properties

White Solid

InChI:InChI=1/C15H30BrNO2/c1-15(2,3)19-14(18)17-13-11-9-7-5-4-6-8-10-12-16/h4-13H2,1-3H3,(H,17,18)

Upstream product

• 23160-46-5 10-amino-1-decanol 
• 24424-99-5 di-tert-butyl dicarbonate 
• 173606-54-7 (10-hydroxydecyl)carbamic acid tert-butyl ester 
• 161270-70-8 2-(10-hydroxydecyl)-1H-isoindole-1,3(2H)-dione 
• 53463-68-6 1-bromo-10-decanol 

Relevant articles and documents

Towards the development of a targeted albumin-binding radioligand: Synthesis, radiolabelling and preliminary in vivo studies

Introduction: The compound named 4-[10-(4-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)butanamido)decyl]-11-[10-(β,D-glucopyranos-1-yl)-1-oxodecyl]-1,4,8,11-tetraazacyclotetradecane-1,8-diacetic acid is a newly synthesised molecule capable of binding in vivo to

RADIOPHARMACEUTICAL CONJUGATE

This invention relates new radiopharmaceutical conjugates for use in improved methods of diagnosis and treatment of cancer. The radiopharmaceutical conjugate comprises, in sequence: a metabolite that targets tumour cells, bound to a chelating agent capable of containing a radionuclide.bound to a linker capable of binding with an EPR agent in vitro or in vivo; or a chelating agent capable of containing a radionuclide, bound to a metabolite that targets tumour cells, bound to a linker capable of binding with an EPR agent in vitro or in vivo. The radiopharmaceutical conjugates of the present invention provide active and passive targeted radionuclide delivery systems that can help to improve the biodistribution and pharmacological toxicity of the radiopharmaceuticals used for the diagnosis and therapy of cancer.